Reduction of HDL levels lowers plasma PLTP and affects its distribution among lipoproteins in mice

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1791, Issue 8, 2009, Pages 790-796

  Samyn, Hannelore ^a   Moerland, Matthijs ^a   van Gent, Teus ^a   van Haperen, Rien ^a   van Tol, Arie ^a   de Crom, Rini ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ATP binding cassette transporter A1; High density lipoprotein; Lipoprotein metabolism; Liver X receptor; Phospholipid transfer protein

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; LIPOPROTEIN BLOOD LEVEL; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DNA-BINDING PROTEINS; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; MICE; PHOSPHOLIPID TRANSFER PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

MUS;

EID: 67650245091     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2009.04.009     Document Type: Article

References (41)

1. Hoffman H.N., and Fredrickson D.S. Tangier disease (familial high density lipoprotein deficiency). Clinical and genetic features in two adults. Am. J. Med. 39 (1965) 582-593
2. Marcil M., Brooks-Wilson A., Clee S.M., Roomp K., Zhang L.H., Yu L., Collins J.A., van Dam M., Molhuizen H.O., Loubster O., Ouellette B.F., Sensen C.W., Fichter K., Mott S., Denis M., Boucher B., Pimstone S., Genest Jr. J., Kastelein J.J., and Hayden M.R. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 354 (1999) 1341-1346
3. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O., Loubser O., Ouelette B.F., Fichter K., Ashbourne-Excoffon K.J., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J., Genest Jr. J., and Hayden M.R. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22 (1999) 336-345
4. Bodzioch M., Orso E., Klucken J., Langmann T., Bottcher A., Diederich W., Drobnik W., Barlage S., Buchler C., Porsch-Ozcurumez M., Kaminski W.E., Hahmann H.W., Oette K., Rothe G., Aslanidis C., Lackner K.J., and Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22 (1999) 347-351
5. Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.C., Deleuze J.F., Brewer H.B., Duverger N., Denefle P., and Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22 (1999) 352-355
6. Cavelier C., Lorenzi I., Rohrer L., and von Eckardstein A. Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim. Biophys. Acta 1761 (2006) 655-666
7. McNeish J., Aiello R.J., Guyot D., Turi T., Gabel C., Aldinger C., Hoppe K.L., Roach M.L., Royer L.J., de Wet J., Broccardo C., Chimini G., and Francone O.L. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4245-4250
8. Orso E., Broccardo C., Kaminski W.E., Bottcher A., Liebisch G., Drobnik W., Gotz A., Chambenoit O., Diederich W., Langmann T., Spruss T., Luciani M.F., Rothe G., Lackner K.J., Chimini G., and Schmitz G. Transport of lipids from Golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat. Genet. 24 (2000) 192-196
9. von Eckardstein A., Chirazi A., Schuler-Luttmann S., Walter M., Kastelein J.J., Geisel J., Real J.T., Miccoli R., Noseda G., Hobbel G., and Assmann G. Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I. J. Lipid Res. 39 (1998) 987-998
10. Francone O.L., Subbaiah P.V., van Tol A., Royer L., and Haghpassand M. Abnormal phospholipid composition impairs HDL biogenesis and maturation in mice lacking Abca1. Biochemistry 42 (2003) 8569-8578
11. Jauhiainen M., Metso J., Pahlman R., Blomqvist S., van Tol A., and Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J. Biol. Chem. 268 (1993) 4032-4036
12. Tu A.Y., Nishida H.I., and Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J. Biol. Chem. 268 (1993) 23098-23105
13. Lee-Rueckert M., Vikstedt R., Metso J., Ehnholm C., Kovanen P.T., and Jauhiainen M. Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells. J. Lipid Res. 47 (2006) 1725-1732
14. Oram J.F., Wolfbauer G., Vaughan A.M., Tang C., and Albers J.J. Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J. Biol. Chem. 278 (2003) 52379-52385
15. Siggins S., Bykov I., Hermansson M., Somerharju P., Lindros K., Miettinen T.A., Jauhiainen M., Olkkonen V.M., and Ehnholm C. Altered hepatic lipid status and apolipoprotein A-I metabolism in mice lacking phospholipid transfer protein. Atherosclerosis 190 (2007) 114-123
16. Jiang X.C., Qin S., Qiao C., Kawano K., Lin M., Skold A., Xiao X., and Tall A.R. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat. Med. 7 (2001) 847-852
17. Yan D., Navab M., Bruce C., Fogelman A.M., and Jiang X.C. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J. Lipid Res. 45 (2004) 1852-1858
18. van Haperen R., van Tol A., van Gent T., Scheek L., Visser P., van der Kamp A., Grosveld F., and de Crom R. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J. Biol. Chem. 277 (2002) 48938-48943
19. van Haperen R., van Tol A., Vermeulen P., Jauhiainen M., van Gent T., van den Berg P., Ehnholm S., Grosveld F., van der Kamp A., and de Crom R. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1082-1088
20. Foger B., Santamarina-Fojo S., Shamburek R.D., Parrot C.L., Talley G.D., and Brewer Jr. H.B. Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J. Biol. Chem. 272 (1997) 27393-27400
21. Wang X., and Rader D.J. Molecular regulation of macrophage reverse cholesterol transport. Curr. Opin. Cardiol. 22 (2007) 368-372
22. Laffitte B.A., Joseph S.B., Chen M., Castrillo A., Repa J., Wilpitz D., Mangelsdorf D., and Tontonoz P. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell Biol. 23 (2003) 2182-2191
23. Cao G., Beyer T.P., Yang X.P., Schmidt R.J., Zhang Y., Bensch W.R., Kauffman R.F., Gao H., Ryan T.P., Liang Y., Eacho P.I., and Jiang X.C. Phospholipid transfer protein is regulated by liver X receptors in vivo. J. Biol. Chem. 277 (2002) 39561-39565
24. Costet P., Luo Y., Wang N., and Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275 (2000) 28240-28245
25. Speijer H., Groener J.E., van Ramshorst E., and van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 90 (1991) 159-168
26. Samyn H., Moerland M., van Gent T., van Haperen R., Metso J., Grosveld F., Jauhiainen M., van Tol A., and de Crom R. Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study. J. Lipid Res. 49 (2008) 2504-2512
27. Oka T., Kujiraoka T., Ito M., Egashira T., Takahashi S., Nanjee M.N., Miller N.E., Metso J., Olkkonen V.M., Ehnholm C., Jauhiainen M., and Hattori H. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J. Lipid Res. 41 (2000) 1651-1657
28. Austyn J.M., and Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur. J. Immunol. 11 (1981) 805-815
29. McCarron R.M., Goroff D.K., Luhr J.E., Murphy M.A., and Herscowitz H.B. Methods for the collection of peritoneal and alveolar macrophages. Methods Enzymol. 108 (1984) 274-284
30. van Haperen R., Samyn H., Moerland M., van Gent T., Peeters M., Grosveld F., van Tol A., and de Crom R. Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis. PLoS ONE 3 (2008) e2255
31. Moerland M., Samyn H., van Gent T., Jauhiainen M., Metso J., van Haperen R., Grosveld F., van Tol A., and de Crom R. Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice. J. Lipid Res. 48 (2007) 2622-2631
32. Naik S.U., Wang X., Da Silva J.S., Jaye M., Macphee C.H., Reilly M.P., Billheimer J.T., Rothblat G.H., and Rader D.J. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113 (2006) 90-97
33. Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J.G., Rubin E.M., and Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992) 343-353
34. Barish G.D., Atkins A.R., Downes M., Olson P., Chong L.W., Nelson M., Zou Y., Hwang H., Kang H., Curtiss L., Evans R.M., and Lee C.H. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4271-4276
35. Nakagami H., Osako M.K., Takami Y., Hanayama R., Koriyama H., Mori M., Hayashi H., Shimizu H., and Morishita R. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis 203 (2009) 51-58
36. Westerterp M., Berbee J.F., Pires N.M., van Mierlo G.J., Kleemann R., Romijn J.A., Havekes L.M., and Rensen P.C. Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation 116 (2007) 2173-2181
37. Plosch T., Kok T., Bloks V.W., Smit M.J., Havinga R., Chimini G., Groen A.K., and Kuipers F. Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J. Biol. Chem. 277 (2002) 33870-33877
38. Grefhorst A., Elzinga B.M., Voshol P.J., Plosch T., Kok T., Bloks V.W., van der Sluijs F.H., Havekes L.M., Romijn J.A., Verkade H.J., and Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277 (2002) 34182-34190
39. Oram J.F., Wolfbauer G., Tang C., Davidson W.S., and Albers J.J. An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux. J. Biol. Chem. 283 (2008) 11541-11549
40. O Brien K.D., Vuletic S., McDonald T.O., Wolfbauer G., Lewis K., Tu A.Y., Marcovina S., Wight T.N., Chait A., and Albers J.J. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation 108 (2003) 270-274
41. Tontonoz P., and Mangelsdorf D.J. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17 (2003) 985-993